Allogeneic haematopoietic stem cell transpantation (HSCT) has become a major life sustaining treatment for haematopoietic disorders, and it is the preffered treatment option for selected patients with idiopatic myelofibrosis. Still, it may be accompanied by various complications.
Here, we present a case of Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD), i.e. an infection-induced malignant proliferation following HSCT.